A consistency-adjusted alpha-adaptive strategy for sequential testing

Statistics in Medicine

Volumn 29, Issue 15, 2010, Pages 1559-1571

  Alosh, Mohamed ^a   Huque, Mohammad F ^a,b  

^a OTS   (United States)

^b GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

Alpha adaptive; Consistency criterion; Multiplicity; Piecewise linear adaptive

Indexed keywords

ANTIDIABETIC AGENT; CAPTOPRIL; LOSARTAN; PIOGLITAZONE; PLACEBO;

ADAPTATION; ADD ON THERAPY; ADULT; ANALYTICAL ERROR; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSISTENCY ADJUSTED ALPHA ADAPTIVE STRATEGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; INTERNAL CONSISTENCY; LINEAR SYSTEM; MAJOR CLINICAL STUDY; METHODOLOGY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STRATEGIC PLANNING; UNSTABLE ANGINA PECTORIS;

ALGORITHMS; BIOSTATISTICS; CAPTOPRIL; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; DIABETIC ANGIOPATHIES; ENDPOINT DETERMINATION; EPIDEMIOLOGIC RESEARCH DESIGN; HEART FAILURE; HUMANS; LOSARTAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIAZOLIDINEDIONES;

EID: 77953771359     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3896     Document Type: Article

References (20)

1. D'Agostino Sr RB. Controlling alpha in a clinical trial: the case for secondary endpoints. Statistics in Medicine 2000; 19:763-766.
2. Moyé LA. Alpha calculus in clinical trials: considerations and commentary for the new millennium. Statistics in Medicine 2000; 19:767-779.
3. Koch GG. Discussion for 'Alpha calculation in clinical trials: consideration and commentary for the new millennium'. Statistics in Medicine 2000; 19:781-784.
4. O'Neill RT. Commentary on 'Alpha calculation in clinical trials: consideration and commentary for the new millennium'. Statistics in Medicine 2000; 19:785-793.
5. O'Neill RT. Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance. Controlled Clinical Trials 1997; 18:550-556. (Pubitemid 27520843)
6. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. New England Journal of Medicine 1996; 334(21):1349-1355. (Pubitemid 26152713)
7. Fisher LD, Moyé LA. Carvedilol and the Food and Drug Administration approval process. Controlled Clinical Trials 1999; 20:16-39.
8. Moyé LA, Baraniuk S. Dependence, hyper-dependence and hypothesis testing in clinical trials. Contemporary Clinical Trials 2007; 28:68-78. (Pubitemid 44780203)
9. Li J, Mehrotra D. An efficient method for accommodating potentially underpowered primary endpoints. Statistics in Medicine 2008; 27:5377-5391.
10. Wiens BL. A fixed sequence Bonferroni procedure for testing multiple endpoints. Pharmaceutical Statistics 2003; 2:211-215.
11. Wiens BL, Dmitrienko A. The fallback procedure for evaluating a single family of hypotheses. Journal of Biopharmaceutical Statistics 2005;15:929-942. (Pubitemid 41540979)
12. Huque MF, Alosh M. A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trials. Journal of Statistical Planning and Inference 2008; 138:321-335.
13. Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Statistics in Medicine 2007; 26:3535-3549. (Pubitemid 47180696)
14. Alosh M, Huque MF. A flexible strategy for testing subgroups and overall populations. Proceedings of the Joint Statistical Meetings, Biopharmaceutical Section 2007; Salt Lake City, UT, 198-203.
15. Alosh M, Huque MF. A flexible strategy for testing subgroups and overall population. Statistics in Medicine 2009; 28:3-23.
16. (R) 9.2 Language Reference. SAS Institute Inc. Cary, NC.
17. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J. On behalf of the PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone clinical trials in macrovascular events): a randomized controlled trial. Lancet 2005; 366:1279-1289.
18. Wilcox R, Bousser M-G, Betteridge DJ, Guntram S, Pirags V, Kupfer S, Dromandy J. Effects of Pioglitazone in patients with or without previous stroke. Stroke, 2007; 38:865-873.
19. Pitt B, Segal R, Martinez FA, Meurers G, Gowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
20. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger GH, Neaton J, Sharma D, Thiyagarajan B. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial-the Losartan Heart Failure Survival Study, ELITE II. Lancet 2000; 355:1582-1587.